InMed's Q2 FY2026 shows revenue declining 26% YoY to $820K, while net loss widened 40% to $3.0M. Operating loss improved 28% to $2.5M, and diluted EPS improved 62% to -$0.73, partly due to a low prior-year base. The balance sheet is not reported, but recent filings reveal a merger agreement and multiple 8-Ks, signaling corporate restructuring and potential dilution.
•Revenue fell 26% YoY to $820K, continuing a downward trend from $1.1M in the prior year.
•Net loss deepened 40% to $3.0M, though operating loss improved 28% to $2.5M, indicating some cost control.
•Diluted EPS improved 62% to -$0.73, but this is partly due to a very weak prior-year EPS of -$1.94.
•Recent filings show a merger agreement (May 2026) and amendments, plus a dilution event in the past 12 months, suggesting capital structure changes ahead.
Informational summary based on SEC XBRL figures · generated by AI agent. Not investment advice.
A Vancouver-based pharma company developing drugs from rare cannabinoids (CBN, CBG, CBC) that plants produce in tiny quantities — using biosynthesis to manufacture them at pharmaceutical scale.
🧬 BioSynt platform synthesizes rare cannabinoids chemically, bypassing the limitations of plant extraction entirely
💊 INM-755 (cannabinol cream) is in clinical trials for epidermolysis bullosa, a rare and severe skin blistering disease
🔬 Rare cannabinoid focus sets InMed apart from the dozens of companies racing to develop CBD- or THC-based drugs
InMed Pharmaceuticals is a Vancouver-based biopharmaceutical company focused on developing drugs from rare cannabinoids such as CBN, CBG, and CBC. Unlike most cannabis companies that work with abundant cannabinoids like THC or CBD, InMed targets cannabinoids that plants produce in only tiny quantities. The company's core technology is its BioSynt platform, which uses biosynthesis to manufacture these rare cannabinoids at pharmaceutical scale, bypassing the limitations of plant extraction entirely. This approach allows InMed to produce consistent, high-purity cannabinoids for clinical development. Their lead drug candidate, INM-755, is a cannabinol cream currently in clinical trials for epidermolysis bullosa, a rare and severe skin blistering disease.
What is InMed Pharmaceuticals' business model?
InMed Pharmaceuticals operates as a pharmaceutical drug development company, not a typical cannabis cultivator or retailer. Its business model centers on discovering and developing proprietary drug candidates based on rare cannabinoids, with a pipeline that advances these candidates through preclinical and clinical trials. The company leverages its BioSynt platform to produce rare cannabinoids via biosynthesis, which enables scalable and cost-effective manufacturing for clinical and potential commercial use. InMed's primary value driver is the successful development and eventual commercialization of its drug candidates, such as INM-755 for epidermolysis bullosa. Revenue generation would come from product sales, licensing agreements, or partnerships with larger pharmaceutical firms, rather than from direct cannabis sales.
What category does InMed Pharmaceuticals (INM) fall under in the cannabis sector?
InMed Pharmaceuticals is classified as a cannabis-related pharmaceutical and biotech company on WeedMarketCap. Unlike multi-state operators (MSOs) or Canadian licensed producers that focus on cultivation, processing, and retail of cannabis flower and extracts, InMed is a drug development firm. It operates at the intersection of biotechnology and cannabinoid science, using synthetic biology to create pharmaceutical-grade cannabinoids. This places it in the ancillary and pharma sub-sector of the cannabis industry, alongside other companies developing cannabinoid-based therapeutics. InMed's focus on rare cannabinoids and its biosynthesis platform differentiate it from the many companies racing to develop CBD- or THC-based drugs, making it a specialized player in the medical cannabis and biotech space.
What makes InMed Pharmaceuticals different from other cannabis drug developers?
InMed Pharmaceuticals stands out from the dozens of companies developing CBD- or THC-based drugs due to its exclusive focus on rare cannabinoids like CBN, CBG, and CBC. These cannabinoids are produced in only trace amounts by cannabis plants, making traditional extraction uneconomical and impractical for pharmaceutical use. InMed's BioSynt platform solves this by chemically synthesizing rare cannabinoids, bypassing plant extraction entirely and enabling production at pharmaceutical scale with high purity and consistency. This technological edge allows InMed to target diseases that may benefit from these understudied cannabinoids. Additionally, its lead candidate INM-755 addresses epidermolysis bullosa, a rare and severe skin blistering disease with no approved treatments, highlighting the company's commitment to unmet medical needs.
What is InMed Pharmaceuticals' lead drug candidate and its target indication?
InMed Pharmaceuticals' lead drug candidate is INM-755, a cannabinol (CBN) cream being developed for the treatment of epidermolysis bullosa (EB), a rare and severe genetic skin disorder that causes extreme blistering and fragility. EB currently has no approved therapies, and patients often suffer from chronic pain, infections, and complications. INM-755 is designed to leverage the anti-inflammatory and wound-healing properties of CBN to improve skin integrity and reduce blistering. The drug is currently in clinical trials, and if successful, could become a first-in-class treatment for EB. This program underscores InMed's strategy of targeting rare diseases with high unmet need, using rare cannabinoids that are difficult to obtain through traditional plant extraction but can be reliably produced via the company's BioSynt biosynthesis platform.
925.9K
Enterprise Value$-372.71K
Shares Outstanding5.34M
As previously reported, InMed Pharmaceuticals Inc.
